# Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes

Study · id `cardio:ct-nct05949281` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05949281](<https://clinicaltrials.gov/study/NCT05949281>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05949281

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 102 participants.

## Technical summary

Registry record NCT05949281. Randomized; double masking; primary purpose treatment. Start 2023-08-29 (actual); primary completion 2031-01-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 102 participants (enrolled count; ClinicalTrials.gov record NCT05949281, source copy `cardio:ctgov-nct05949281-2026-07-13`, retrieved 2026-10-26)
- Started: 2023-08-29 (actual) (ClinicalTrials.gov record NCT05949281, source copy `cardio:ctgov-nct05949281-2026-07-13`, retrieved 2026-10-26)
- Primary completion: 2031-01-15 (anticipated) (ClinicalTrials.gov record NCT05949281, source copy `cardio:ctgov-nct05949281-2026-07-13`, retrieved 2026-10-26)
- Completion: 2031-01-15 (anticipated) (ClinicalTrials.gov record NCT05949281, source copy `cardio:ctgov-nct05949281-2026-07-13`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT05949281, source copy `cardio:ctgov-nct05949281-2026-07-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05949281-2026-07-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes
- Acronym: REC1TE
- Condition: Type 1 Diabetes
- Condition: Cardiovascular Diseases
- Condition: Chronic Inflammation
- Intervention (Drug): Colchicine 0.5 MG Oral Tablet
- Intervention (Drug): Placebo
- Lead sponsor: Asger Lund, MD
- Lead sponsor class: OTHER
- Collaborator: University of Copenhagen
- Collaborator class: OTHER
- Collaborator: Juvenile Diabetes Research Foundation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Type 1 diabetes (`core:type-1-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Colchicine (`cardio:colchicine`)
- Registry lists this organization as a collaborator: University of Copenhagen (`cardio:org-university-of-copenhagen`)
- Registry lists this organization as a collaborator: Juvenile Diabetes Research Foundation (`cardio:org-juvenile-diabetes-research-foundation`)

## Provenance

Content hash: 8dd24a67003caa708a5f6596441dbf1af4c29bede190b4ae0fb2e91d530e715a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
